What is beyond the Nivolumab Monotherapy approval for advanced Hepatocellular Carcinoma? by Luis Mendoza in Open Access Journal of Oncology and Medicine (OAJOM) in Lupine Publishers
With an estimated 500,000 new cases per year, hepatocellular carcinoma
(HCC) represents the third leading cause of cancer death worldwide. The
incidence is rising in the west, largely due to an increasing incidence
of hepatitis C virus infection [1]. The majority of HCC patients are
diagnosed with disease too advanced for curative treatment. Only liver
resection and liver transplantation are considered curative, with poor
efficiency of other modalities such as radiofrequency ablation (RFA) and
transarterial chemoembolization (TACE), although this may provide a
modest prolongation in survival; however, the relapse in the majority of
these patients is inevitable [2]. An array of translational research
and pilot clinical trials have revealed that adoptive immunotherapy’s
are safe by patients with HCC, but they lack efficacy [3]. Now, we are
in the new era of immunotherapy’s such as immune checkpoint inhibitors
and CAR-T strategies, which would bring benefit to the HCC patients.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.